Wagner also previously worked at Gilead Sciences, where he was director of cell biology and a member of Gilead's management team. While at Gilead, Wagner led the development of antisense therapeutics, and was engaged in a collaboration with Glaxo Wellcome (now GlaxoSmithKline). At Gilead, Wagner was an inventor on several technologies related to antisense therapeutics and delivery methodologies.
Steven Samuelsson, Richard Wagner, Owen Dempsey
SRI International announced last week that Steven Samuelsson has joined SRI's Biosciences Division as director of imaging. He will lead efforts in microscopy and imaging-based assays for drug discovery and development.
Samuelsson joins SRI from (OSI) Eyetech Pharmaceuticals, where he was associate director of experimental pathology. In that role, he provided imaging expertise in anti-angiogenesis studies for drug discovery and delivery programs.
Prior to (OSI) Eyetech Pharmaceuticals, Samuelsson was a senior scientist at Procter & Gamble Pharmaceuticals, where he led the Cell and Molecular Imaging Group. He was a member of bone, muscle, and vascular biology teams within the company.
SRU Biosystems said this week that Richard Wagner has joined the company as president and chief executive officer and as a member of the board of directors. Wagner replaces Owen Dempsey, who resigned from the company to pursue other interests.
Wagner had been an advisor to SRU Biosystems since 2002.
Wagner was most recently executive vice president of research at Praecis Pharmaceuticals, where he was an inventor of the DirectSelect small-molecule screening technology that led to the creation of a ten billion compound screening library. Wagner negotiated collaborations with both Gilead Sciences and GlaxoSmithKline, and the DirectSelect technology and Praecis were both purchased by GlaxoSmithKline in February 2007.
Prior to joining Praecis, Wagner started operations at Phylos in July 1997, where he held the position of senior vice president of research. At Phylos, Wagner was an inventor of several technologies, including a class of antibody mimetics called Adnectins, protein microarray applications, and multiplex diagnostic technologies. At Phylos, Wagner was involved in securing an agreement with Hoechst (now Sanofi-Aventis), as well as a Series B financing.